PNC27
Also known as: PNC-27, p53-HDM2 Disruptor Peptide, Anti-Cancer Peptide PNC-27
Key Facts: PNC27
- Category
- Immune
- FDA Status
- Not FDA Approved
- Clinical Status
- Preclinical - Extensive in vitro studies, ex vivo human cancer tissue studies
- Administration
- IV injection in animal studies - not for human use
- Typical Dose
- No human dose - research compound only
- Frequency
- Not applicable - no human use
- Duration
- Research protocols only - no human use data
Mechanism of Action
The hook is selectivity. Many cancer cells display the protein HDM-2 (the human version of MDM2) on their outer membrane, while most normal cells keep it tucked inside. PNC-27 carries the part of p53 that normally docks onto HDM-2, so it latches onto that membrane-bound HDM-2 on cancer cells. Once anchored there, the peptide's amphipathic helix-loop-helix structure inserts into the membrane and forms pores, causing the cell to rupture and die by necrosis rather than the slower apoptosis pathway. The peptide has also been reported to disrupt mitochondrial membranes after entering the cell. Normal cells that lack membrane HDM-2 are reported not to bind the peptide and survive, which is the basis for the selectivity claim.
Research Summary
The mechanistic story is backed by real peer-reviewed work, most notably a 2010 paper in PNAS (Sarafraz-Yazdi and colleagues) showing PNC-27 adopts an HDM-2-binding shape and kills cancer cells by binding HDM-2 in their membranes, plus a 2010 study confirming the intact peptide causes tumor cell lysis. Follow-up work, including a 2022 paper in Biomedicines, reinforced the membrane-pore model and selectivity in cell lines and showed transfecting membrane HDM-2 into normal cells makes them vulnerable too. Crucially, all of this is in vitro and in animal models. There are no completed human clinical trials demonstrating safety or anticancer benefit in patients, so any claim that PNC-27 treats cancer in people is not supported. It is a genuinely intriguing preclinical anticancer concept that has not crossed into proven human therapy, and self-experimentation is not justified by the data.
Dosing Information
Note: Animal study doses may not translate directly to humans.
Typical Dosingⓘ
Community experience
No human dose - research compound only
Lab research: 0.1-0.3 mg/mL in cell culture
Not applicable - no human use
Experimental anti-cancer peptide with strong lab evidence but NO human clinical trials. Research shows 0.2-0.3 mg/mL kills 90-100% of cancer cells in vitro while sparing normal cells. Only tested in cell cultures and ex vivo tissue samples. Not available through peptide vendors - strictly a research compound for cancer biology studies.
Research Dosingⓘ
Scientific studies
Lab concentrations from peer-reviewed studies - no human dosing established
Doses from Studies
0.3 mg/mL (nearly 100% leukemia cell killing)
0.1-0.5 mg/mL range tested in vitro
PNAS 2010 - Anticancer peptide PNC-27 adopts HDM-2-binding conformation ↗
0.2 mg/mL (90-92% ovarian cancer reduction)
Annals of Clinical & Laboratory Science 2015 - Ex vivo efficacy in patient-derived ovarian cancer ↗
Duration
Research protocols only - no human use data
Administration
IV injection in animal studies - not for human use
Timing & Administration
Best Time to Take
Per research protocol
Research protocols only
Food Recommendation
With or without food
Why This Timing?
Experimental compound with short half-life. In vitro studies show optimal activity at 37°C with peptide re-addition every 24 hours.
Possible Side Effects
Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.
- ●Limited safety data - research compound only
- ●Highly selective for cancer cells in vitro
- ●No cytotoxicity observed in normal cells (fibroblasts, leukocytes)
- ●Temperature-dependent activity (37°C optimal, minimal at 17°C)
- ●Not tested in human clinical trials
- ●Unknown systemic effects in humans
- ●Potential immunogenicity unknown
References
- https://www.pnas.org/doi/10.1073/pnas.0909364107
- https://pmc.ncbi.nlm.nih.gov/articles/PMC2836618/
- https://pubmed.ncbi.nlm.nih.gov/20182728/
- https://www.mdpi.com/2227-9059/10/5/945
- https://pmc.ncbi.nlm.nih.gov/articles/PMC9138867/
Research This Peptide Further
Frequently Asked Questions
What does PNC27 do?
PNC-27 is a 32-amino-acid lab-designed peptide that fuses a fragment of the tumor-suppressor protein p53 (residues 12 to 26) to a membrane-penetrating leader sequence. The interesting claim is that it kills cancer cells while leaving normal cells alone, by punching holes in the cancer cell membrane. It is a research compound only, with no approval and no human clinical trials.
How does PNC27 work?
The hook is selectivity. Many cancer cells display the protein HDM-2 (the human version of MDM2) on their outer membrane, while most normal cells keep it tucked inside. PNC-27 carries the part of p53 that normally docks onto HDM-2, so it latches onto that membrane-bound HDM-2 on cancer cells. Once anchored there, the peptide's amphipathic helix-loop-helix structure inserts into the membrane and forms pores, causing the cell to rupture and die by necrosis rather than the slower apoptosis pathway. The peptide has also been reported to disrupt mitochondrial membranes after entering the cell. Normal cells that lack membrane HDM-2 are reported not to bind the peptide and survive, which is the basis for the selectivity claim.
Is PNC27 FDA approved?
No, PNC27 is not currently FDA approved. Current status: Preclinical - Extensive in vitro studies, ex vivo human cancer tissue studies
What are the side effects of PNC27?
Reported side effects include: Limited safety data - research compound only, Highly selective for cancer cells in vitro, No cytotoxicity observed in normal cells (fibroblasts, leukocytes), Temperature-dependent activity (37°C optimal, minimal at 17°C), Not tested in human clinical trials. Individual responses vary based on dosage, duration, and personal health factors.
What is the typical dose of PNC27?
Community-reported common dose: No human dose - research compound only (Not applicable - no human use). Range: Lab research: 0.1-0.3 mg/mL in cell culture. Administration: IV injection in animal studies - not for human use. Research compound only. No human clinical data. Not for human use. Lab research only.
Related Peptides
Peptides commonly compared with PNC27 or used in similar applications.
KPV
PreclinicalKPV is a tiny tripeptide, just three amino acids (lysine, proline, valine), that forms the tail end of the natural hormone alpha-MSH. It is studied almost entirely as an anti-inflammatory agent, particularly for gut and skin inflammation. There are no registered human clinical trials proving its benefits in people; the evidence base is cell-culture and animal studies, so anything you read about it treating disease is preliminary.
ImmuneLL-37
Clinical TrialsLL-37 is the only cathelicidin antimicrobial peptide humans make, a 37-amino-acid, positively charged, helical fragment cut from a precursor protein called hCAP-18. It is a frontline player in the innate immune system, part of the body's chemical defense against bacteria, viruses, and fungi. This is mainstream, heavily studied human biology, not a fringe research peptide, though LL-37 itself is not an approved drug.
ImmuneThymosin Alpha-1
Clinical TrialsThymosin alpha-1 (sold as Zadaxin, generic name thymalfasin) is a 28-amino-acid peptide originally isolated from the thymus gland, the organ that trains your immune system. Unlike most peptides in this space, it is a real, approved drug in over 35 countries for chronic hepatitis B and as an immune booster, though it has never been approved by the FDA in the United States. It has one of the larger human evidence bases of any peptide here, with trials in tens of thousands of patients.
ImmuneVIP
Clinical TrialsVIP (vasoactive intestinal peptide) is a 28-amino-acid signaling peptide your own gut, nerves, and immune cells make. It is a natural anti-inflammatory and a potent vasodilator, and a synthetic version called aviptadil has been tested in humans for COVID-19 respiratory failure and pulmonary conditions. No VIP product is FDA-approved for the wellness or anti-aging uses it gets marketed for, and most of that human data is in lung disease, not in healthy people.
ImmuneEnfuvirtide
FDAEnfuvirtide (brand name Fuzeon, originally T-20) is a 36-amino-acid synthetic peptide and the first HIV fusion inhibitor, FDA-approved in March 2003. It is a genuine prescription antiretroviral, not a research-only compound, and it is given as a twice-daily subcutaneous injection. Its job is narrow but important: it blocks HIV from entering a host cell in the first place, and it is reserved for people whose virus has stopped responding to other drugs.
ImmuneThymogen
Clinical TrialsThymogen is the brand name for L-Glu-L-Trp (glutamyl-tryptophan, the dipeptide EW), an immune-modulating peptide isolated from the calf thymus extract Thymalin. It is the smallest active piece of that thymic complex and is studied for boosting T-cell activity and immune function. It has been used clinically in Russia since 1990 but has never been evaluated or approved by any Western regulator, and rigorous independent trials are lacking.
ImmuneWant updates on PNC27 research?
Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.